Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After posting flat revenue growth during FY24, Info Edge-backed edtech platform Coding Ninjas demonstrated 26.4% year-on-year growth in its operating revenue in the last fiscal year. Significantly, ...

Somdip is the Chief Scientist of Nosh Technologies, an MIT Innovator Under 35 and a Professor of Practice (AI/ML) at the Woxsen University. This may sound like science fiction, but the convergence of ...

Creating an iPhone app without prior coding experience may seem daunting, but advancements in artificial intelligence are making this process more accessible. This article explores how a non-developer ...

The VP of engineering at a leading technology company stared at the quarterly adoption metrics with growing frustration. Twelve months after rolling out a state-of-the-art AI coding assistant—a tool ...

Meta told employees that it is going to allow some coding job candidates to use an AI assistant during the interview process, according to internal Meta communications seen by 404 Media. The company ...

Kiro’s structured, agentic workflow challenges the Copilot model, offering a spec-first IDE with hooks, task orchestration, and enterprise-grade design generation. AWS has previewed Kiro, a new ...

After two and a half years we have enough data to form a clearer picture about who is using AI, what they are using it for, what they think about it, and what it means for learning. What do students ...

Forbes contributors publish independent expert analyses and insights. Davey Winder is a veteran cybersecurity writer, hacker and analyst. Vibe coding isn’t what a lot of people seem to think it is.

The Electrical and Computer Engineering Building, which connects to the Paul G. Allen Center for Computer Science & Engineering, on a sunny afternoon in June 2025. (GeekWire Photo / Lisa Stiffler) The ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...

Either way, let’s not be in denial about it. Credit...Illustration by Christoph Niemann Supported by By Kevin Roose and Casey Newton Kevin Roose and Casey Newton are the hosts of The Times’s “Hard ...